Drug Database
Back to search

Poland· PL-100163845

Geloplasma

A blood substitutes and plasma protein fractions product containing preparat złożony, registered in Poland by Fresenius Kabi Polska Sp. z o.o.. The same ATC class is registered in 7 of our 19 countries.

ATC B05AA

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedGeloplasmaATCB05AAREGISTER NO.PL-100163845PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about preparat złożonyAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Preparat złożony is registered in 7 of 19 countries.

Countries holding a registration under ATC B05AA (blood substitutes and plasma protein fractions), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 4 of them publish a price we can compare per daily dose
Search preparat złożony products by name

Preparat złożony · ATC B05AA

7 / 19 countries

  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Preparat złożony
Manufacturer
Fresenius Kabi Polska Sp. z o.o.
Country
Poland (PL)
ATC code
B05AA
ATC class
Blood substitutes and plasma protein fractions
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990818372
  • gtin
    05909990620685

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under B05AA

Blood substitutes and plasma protein fractions, as other registers publish it.

All preparat złożony products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4b61a341-f55b-4b7e-93cc-5d95e12d5898
GET /v1/drugs/4b61a341-f55b-4b7e-93cc-5d95e12d5898?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do infuzji",
  "source": "urpl",
  "strength": "-",
  "packaging": "05909990818372 ¦ Lz ¦ 23384\n20 worków 500 ml\n05909990620685 ¦ Lz ¦ 33847\n15 worków 500 ml",
  "substance": "Gelatina 3 g + Natrii chloridum 0.5382 g + Magnezu chlorek sześciowodny 0.0305 g + potasu chlorek 0.0373 g + Sodu (S)-mleczan 0.336 g",
  "common_name": "Preparat złożony",
  "pl_product_id": "100163845",
  "pozwolenie_nr": "12422",
  "auth_procedure": "MRP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about preparat złożony.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console